Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina
AssigneeThe Research Foundation for The State University of New York
InventorStewart Bloomfield
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of treating a condition of the retina by administering an inhibitor of connexin 36 and/or an inhibitor of connexin 45 to a subject with a retinal condition. This disclosure further provides compositions for the treatment of a retinal condition which include an inhibitor of connexin 36 and/or an inhibitor of connexin 45.
Claims3
A method of treating glaucoma by blocking gap junctions comprising administering a therapeutically effective amount of a non-selective inhibitor of connexin 36 to a subject in need thereof, wherein said non-selective inhibitor is 18-Beta-glycyrrhetinic acid (18Beta-GA), and wherein the therapeutically effective amount is at a concentration of 25 μM.
Dependencies are inferred from the claim text.